Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

Novartis Investigative Site, Taipei

Novartis Investigative Site, George Town

Novartis Investigative Site, Edirne

Novartis Investigative Site, Istanbul

Novartis Investigative Site, Kuala Lumpur

Northwestern University Med School, Chicago

Novartis Investigative Site, Tainan City

Novartis Investigative Site, Kuching

Novartis Investigative Site, Hanoi

Novartis Investigative Site, Beijing

Novartis Investigative Site, Beijing

Novartis Investigative Site, New Delhi

Novartis Investigative Site, Hisar

Novartis Investigative Site, Changchun

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Nanjing

Novartis Investigative Site, Nanjing

Novartis Investigative Site, Xuzhou

Novartis Investigative Site, Tianjin

Novartis Investigative Site, Tianjin

Novartis Investigative Site, Tianjin

Novartis Investigative Site, Fuzhou

Novartis Investigative Site, Changsha

Novartis Investigative Site, Wuhan

Novartis Investigative Site, Zhengzhou

Novartis Investigative Site, Guangzhou

Novartis Investigative Site, Chengdu

Massachusetts General Hospital, Boston

Novartis Investigative Site, CABA

Novartis Investigative Site, Rio de Janiero

Novartis Investigative Site, Blumenau

Novartis Investigative Site, São Paulo

Novartis Investigative Site, Edmonton

Novartis Investigative Site, London

Novartis Investigative Site, Chennai

Novartis Investigative Site, Seoul

Novartis Investigative Site, Seoul

Novartis Investigative Site, Seoul

Novartis Investigative Site, Seoul

Novartis Investigative Site, Ankara

Novartis Investigative Site, Adana